4//SEC Filing
Meisner Lara 4
Accession 0000950170-25-041546
CIK 0002023658other
Filed
Mar 17, 8:00 PM ET
Accepted
Mar 18, 6:35 PM ET
Size
13.0 KB
Accession
0000950170-25-041546
Insider Transaction Report
Form 4
Meisner Lara
Chief Legal Officer
Transactions
- Exercise/Conversion
Common Stock
2025-03-14$5.45/sh+79,146$431,346→ 79,145 total - Sale
Common Stock
2025-03-14$13.24/sh−30,620$405,513→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-03-14−48,720→ 107,187 totalExercise: $5.45Exp: 2033-12-14→ Common Stock (48,720 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-03-14−30,246→ 67,119 totalExercise: $5.45Exp: 2033-12-14→ Common Stock (30,246 underlying) - Sale
Common Stock
2025-03-14$12.69/sh−48,526$615,698→ 30,620 total
Footnotes (5)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.05 to $13.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.05 to $13.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F4]25% of the shares underlying this option vested on November 27, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- [F5]The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date.
Documents
Issuer
Bicara Therapeutics Inc.
CIK 0002023658
Entity typeother
Related Parties
1- filerCIK 0001883986
Filing Metadata
- Form type
- 4
- Filed
- Mar 17, 8:00 PM ET
- Accepted
- Mar 18, 6:35 PM ET
- Size
- 13.0 KB